2+ homeostasis have not been studied in isolated myocardium from patients with hypertensive heart disease (HHD) and heart failure with preserved ejection fraction (HFpEF). Prolonged myocardial relaxation is believed to play an important role in the pathophysiology of these conditions. In this study, we evaluated relaxation parameters, myocardial calcium (Ca 2+ ), and sodium (Na + ) handling, as well as ion transporter expression and tested the effect of Na + -influx inhibitors on relaxation in isolated myocardium from patients with HHD and HFpEF.
T
he prevalence of hypertensive heart disease (HHD), defined as a history of hypertension in association with concentric left ventricular (LV) remodeling or hypertrophy (LVH), has reached epidemic proportions.
1-3 About 2 in 10 adults have HHD, and the prevalence is increasing, even among adolescents. 4 HHD is associated with diastolic dysfunction and is the most common substrate for heart failure with preserved ejection fraction (HFpEF) . Longitudinal population studies in hypertensive patients have demonstrated that diastolic function declines over time. 5 Thus, progression of HHD-dependent diastolic dysfunction is a major reason for the increasing prevalence of HFpEF. 6 Limited understanding of the underlying pathophysiological processes leading to diastolic dysfunction contributes to the fact that HFpEF remains the only major cardiovascular condition without evidence-based therapies.
Increased LV passive stiffness has been reported in HFpEF patients and is ascribed to changes in structural proteins, such as collagen and titin. [7] [8] [9] [10] Active relaxation may also be impaired in LVH and HFpEF. 11 In isolated myocardium from patients with concentric LVH caused by hypertension or aortic stenosis, we recently reported that a heart rate-dependent worsening of relaxation results in diastolic tension generation at rates above 105 per minute, which introduces a dynamic component to stiffness. 12 Our analysis of post-rest contractions and rapid-cooling contractures suggested the presence of inappropriately elevated calcium (Ca 2+ ) levels in myocardium from patients with LVH. The underlying defect seemed to be inadequate sarcolemmal Ca 2+ removal, that could not be compensated by an increase in sarcoplasmic reticulum Ca 2+ sequestration. These results provided the rationale for the design of the present study.
Ca
2+ removal from cardiomyocytes largely depends on the sarcolemmal Na + /Ca 2+ exchanger (NCX)-a transporter driven by the transsarcolemmal Na + gradient. 13 Increased intracellular Na + levels reduce the Na + gradient and limit the ability of NCX to efficiently extrude cellular Ca 2+ . This mechanism provides an explanation for the beneficial effects of Na + -influx inhibition with ranolazine in ischemia (the Na + paradigm) [14] [15] [16] [17] [18] [19] [20] -this mechanism has also been proposed to play a role in HFpEF. 21 If this paradigm applies, reducing Na + influx could increase NCX-mediated Ca 2+ extrusion and thereby improve myocardial relaxation in patients with HFpEF.
The goal of the present study was 3-fold. First, we characterized the mechanical behavior of isolated contracting myocardium obtained from control subjects and HHD patients with and without HFpEF. Second, to gain insight into the mechanisms that impair active relaxation, we directly assessed Ca 2+ and Na + levels and determined expression levels of the underlying ion-transporting systems. Third, we investigated whether pharmacological Na + -influx inhibitors would improve relaxation.
METHODS

General Approach
The study cohort consisted of 61 male and 23 female patients recruited to undergo an intraoperative LV myocardial biopsy from among those scheduled for coronary artery bypass grafting at the University of Vermont Medical Center in Burlington, VT. All patients signed consent forms approved by the University of Vermont Institutional Review Board. LV anterior wall myocardial biopsies were obtained from the epicardial surface as described previously. 7, 22 Electrically excitable strip preparations were sculpted from the biopsies and used to assess mechanical parameters, Ca 2+ and Na + handling and responses to Na + -influx inhibitors. Gene expression, protein quantification, and elemental ion concentrations were investigated in frozen tissue samples.
Clinical Measurements
Demographics, medications, laboratory data, echocardiographic measurements, and cardiac catheterization results were tabulated. The severity of coronary artery disease was graded based on the number of major vessels (left main, left anterior descending, left circumflex, and right coronary artery) with a stenosis >70%. Patients also underwent echocardiographic evaluation to assess LV structure and function. Relative wall thickness was defined as 2×posterior wall in diastole/LV end-diastolic diameter. Similarly, LV mass (grams) was calculated as follows: 0.8×1.04×([LV end-diastolic diameter+interventricular septum in diastole+posterior wall in diastole]^3−LV end-diastolic diameter^3)+0.6.
Inclusion Criteria
Adult patients scheduled to undergo coronary artery bypass grafting with preserved left ventricular ejection fraction (≥50% by echocardiography), normal wall motion, and end-diastolic volume index (≤75 mL/m 2 ) were eligible.
WHAT IS NEW?
• Studies in excitable myocardial strip preparations obtained from patients with HHD and HFpEF have prolonged contraction and relaxation times and incomplete relaxation at high stimulation rates.
• Myocardial calcium levels are elevated in these muscle strips, whereas myocardial sodium levels are unchanged.
• The Na + -influx inhibitors ranolazine, furosemide, and amiloride did not improve relaxation.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Incomplete relaxation may increase LV end diastolic pressure and limit LV systolic reserve by reducing LV end-diastolic volume.
• Neutral findings with Na + -influx inhibitors, including ranolazine, weaken the rationale for their clinical evaluation in HFpEF.
Similar to our previous work, patients were categorized into 3 groups: (1) referent controls without hypertension (control patients [CTR]), (2) HHD, and (3) HHD with HFpEF (HHD+HFpEF). 7 CTR patients fulfilled the general inclusion criteria. HHD patients fulfilled the general inclusion criteria and had a documented and confirmed history of hypertension plus echocardiographic evidence of concentric remodeling or overt hypertrophy (relative wall thickness ≥0. 42 or LVH mass >115 g/m 2 in men, >95 g/m 2 in women) but no evidence of heart failure as defined below. HHD+HFpEF patients fulfilled the general inclusion criteria and had HHD and evidence of HFpEF based on the European Society of Cardiology and Heart Failure Society of America criteria: (1) left ventricular ejection fraction ≥50%, (2) LV end-diastolic volume index <75 mL/m 2 , (3) presence of at least 1 symptom (dyspnea at rest or with minimal exertion or orthopnea) or 1 sign of heart failure (pulmonary crackles, elevated jugular venous pressure, or peripheral edema), (4) evidence of diastolic LV dysfunction obtained by cardiac catheterization (LV end-diastolic pressure >16 mm Hg) or elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels (>1000 ng/mL), and (5) exclusion of noncardiac diseases that could result in symptoms commonly present in heart failure.
7,23
Exclusion Criteria
Patients were excluded if they had one or more of the following: LV wall motion abnormality, left ventricular ejection fraction <50%, LV end-diastolic volume index >75 mL/m 2 , more than moderate valvular stenosis or regurgitation, severe chronic pulmonary disease, any noncardiac disease or condition known to affect myocardial function, anemia (hemoglobin <11 g/dL in men and <10 g/dL in women), serum creatinine >2.0 mg/dL, off-pump or emergency cardiac surgery, history of substance abuse, inability to provide informed consent, active malignancy, severe connective tissue disease, severe liver disease, hypertrophic cardiomyopathy or other restrictive cardiomyopathies, and constrictive pericarditis.
Biopsy Procurement
Intraoperative LV anterior wall epicardial biopsies were obtained as described previously. 11, 12, 24, 25 Biopsies typically weighing between 10 to 40 mg were obtained during coronary artery bypass grafting surgery soon after the patients were placed on cardiopulmonary bypass. The biopsy was immediately submerged in oxygenated ice-cold physiological Krebs buffer containing 30 mmol/L 2,3-butanedione monoxime. If the biopsy was of sufficient size, small quantities (5-15 mg) were removed and flash-frozen for later analysis (gene expression, protein, and elemental analysis). Given the small tissue sample size, not all protocols could be performed on each biopsy. Obtaining contractile data and loading with ion-sensitive fluorescent dyes was prioritized. Because of variations in the subepicardial muscle fiber orientation and excisional tissue damage, only about half the biopsies could be sculpted into contracting preparations and only a third of these could be successfully loaded with fluorescent dyes as demonstrated by the presence of Ca 2+ transients. HHD+HFpEF biopsies, which have more fibrosis, were the most difficult to process. 7 Contractile studies were performed within 12 hours of biopsy procurement.
Muscle Preparation and Mechanical Parameters
Using microdissection scissors, the biopsies were sculpted along the principal muscle fiber orientation into strip preparations with an average cross-sectional area of 1.0±0.4 mm 2 . 22 After the attachment of omega-shaped platinum clips, strip preparations were transferred to a loading chamber that contained the fluorescent ion dyes, as described below. Thereafter, they were transferred into a tissue bath containing oxygenated Tyrode solution at 37°C and attached to a KG4 force transducer (Scientific Instruments, Heidelberg, Germany) with a stimulation unit (MyoPacer; IonOptix, MA). After an equilibration period of 20 to 30 minutes during which isometric force was evoked at a stimulation rate of 30 per minute and resting tension was gradually increased until the developed force reached a maximum (Lmax), force parameters were assessed on a digital recording system (IonWizard 6.3; IonOptix, MA). The following force parameters were recorded: systolic peak tension, diastolic tension, and developed contractile force. The analyzed twitch parameters included time to peak tension, time to 50% and 90% relaxation (RT 50 and RT 90 ), and the time constant of relaxation (τ) calculated from nonlinear least-squares fitting of a single exponential equation to the force data after the time of maximum relaxation rate (−dF/ dtmax). The principal mechanical analyses were performed at stimulation rates of 60 and 180 per minute, respectively. In some preparations, the rate between 60 to 180 per minute was incrementally increased in 30 per minute steps. As previously, core hypoxia was excluded by stopping the perfusion for ≤25 seconds to demonstrate that preparations were mechanically stable and, therefore, sufficiently oxygenated.
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Calcium and Sodium Measurements
Strip preparations were loaded at room temperature in an airtight 1.5 mL loading chamber containing the acetoxymethylester forms of the calcium dye Fura-2 (0.05 mmol/L) and the sodium dye AsanteNATRIUMGreen-2 (0.05 mmol/L) in 2,3-butanedione monoxime Krebs solution containing 0.1% pluronic acid and 0.5% dimethyl sulfoxide for between 1 to 2 hours (all TefLabs, Austin, TX). Thereafter, the strip preparations were transferred to a custom-designed tissue chamber mounted on an inverted microscope (Nikon ECLIPSE TS100 with a T1-SM stage). The light source used for excitation was a 75-W xenon arc-bulb (UXL-75XE; Ushio Corp, Japan) in addition to a galvo-controlled dichroic mirror, which interleaved the excitation bandpass filters at 380 and 485 nm (IonOptix, MA). This choice of excitation filters takes advantage of the lack of excitation of Fura-2 at 485 nm and of AsanteNATRIUMGreen-2 at 380 nm. Continuous recording of the emitted fluorescence at 510 nm using a PMT400 photomultiplier effectively provided simultaneous monitoring of free intracellular Ca 2+ by Fura-2 and intracellular Na + by AsanteNATRIUMGreen-2 at a 250 Hz interleaving frequency. Background fluorescence was not assessed.
In some preparations, ouabain (30 µM) and sodium-binding benzofuran isophthalate (0.05 mmol/L) were used to document changes in cellular Na + . The fluorescence data were digitally recorded and analyzed (IonWizard 6.3; IonOptix, MA). Comparison of RT 50 and force measurements of dyeloaded and unloaded preparations did not reveal a significant effect of the loading solution on the mechanical function of the preparations.
Quantitative Polymerase Chain Reaction and Western Blot
Real-time polymerase chain reaction was performed on an Applied Biosystems 7500 real-time polymerase chain reaction analyzer on the following targets: sarcoplasmic reticulum Ca 2+ -ATPase 2 isoform a, phospholamban, NCX (1.1, 1.3, and 1 variant B), voltage sensitive Ca 2+ channel (CaV1.2α1C=CC), RYR2 (cardiac ryanodine receptor), CASQ2 (cardiac calsequestrin), PMCA4, PMCA1 (plasma membrane Ca 2+ -ATPase), MHC (myosin heavy chain) isoforms α and β (MHCα and MHCβ), Na + /K + -ATPase subunits (1A1, 1A2, 1A3, and 1B1), Na + channel (Nav1.5, Navβ-1, and Navβ-2), and the Na + /H + exchanger (NHE-1). Total RNA was extracted from 3 to 10 mg of muscle tissue using the MELT total nucleic acid isolation system (Ambion, Austin, TX). After enzymatic digestion of the tissue, nucleic acids were bound to magnetic beads and purified by sequential washing steps, as well as a final DNAase treatment. After the RNA was eluted, it was quantified, and the sample purity was tested (Nanodrop; Wilmington, DE and Agilent Bioanalyzer; Agilent Technologies, Santa Clara, CA). Reverse transcription using random primers was performed on the RNA samples using the high-capacity cDNA reverse transcription kit PN 4368813 (Applied Biosystems, Carlsbad, CA). The thermocycler was programmed at 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes, followed by 4°C. The same amount of cDNA was used for all samples. Each sample was run in triplicate. Beta-2-microglobulin (β2 m) was used as an endogenous control. The TaqMan gene expression assay was performed on an ABI 7500 system using the 96-well standard reaction protocol. The ramp rate was standard, the reaction volume was 20 µl, uracil-N-glycosylase incubation occurred at 50°C for 2 minutes, followed by polymerase activation at 95°C for 10 minutes. After the activation of the polymerase was the polymerase chain reaction portion with 40 cycles of 95°C for 15 seconds followed by 60°C for 1 minute. Data were collected, and downstream analysis was conducted using DataAssist Software (Applied Biosystems, Carlsbad, CA). Cycle threshold values were used to call message presence; relative expression was calculated in reference to the endogenous control. Immunoblots of the target proteins phospholamban and calsequestrin were performed according to our previous work.
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Elemental Analysis
Elemental analysis was performed as described previously. 28 Standards and nitric acid were purchased from Sigma-Aldrich (St. Louis, MO). Conical polypropylene tubes of 15 mL volume were soaked in 0.4 mmol/L ethylene glycol tetraacetic acid overnight, and then rinsed with ddH 2 O and air dried. From biopsies of sufficient size, 10 to 15 mg of tissue was lyophilized by vacuum freeze drying for 90 minutes. Samples were then digested in 10 µL nitric acid (15.8 normal) per mg tissue wet weight. Finally, ddH 2 O was added to bring the total volume to a 200-fold dilution of original wet weight, including final concentrations of 0.8 N nitric acid. Standards were prepared for elements Ca, Cu, Fe, Mg, Na, P, S, and Zn, all including 0.8 N nitric acid. Detection of element content was performed using inductively coupled plasma atomic emission spectroscopy performed by ULTIMA2C operated in mono-mode (Horiba Scientific, Edison, NJ). All elements except Na were examined using a G1 sheath argon gas flow setting; Na was examined using the G3 setting. Element content was detected in triplicate for each sample and normalized to tissue wet weight.
To validate inductively coupled plasma atomic emission spectroscopy to detect differences in myocardial Ca content, we conducted an analysis of LV myocardium from sarcoplasmic reticulum calsequestrin overexpressing mice (CSQ OE ; n=4) against their littermate controls (CSQ CTL ; n=3). We found myocardial Ca to be elevated by >3-fold (CSQ OE 510±62 ppm versus CSQ CTL 164±29 ppm; P<0.01). These results confirm that inductively coupled plasma atomic emission spectroscopy can detect differences in myocardial elemental contents as would be expected in these transgenic mice.
Sodium Influx Inhibition
The following clinically relevant and modifiable sources of cellular Na + influx were studied: Na + channel (I Na -late current), Na
− cotransporter, and Na + /H + antiporter (NHE-1). After establishing a baseline steady state at 60 and 180 per minute, the I Na -late current inhibitor ranolazine (10 µM) was added to the circulating solution. After 15 minutes, the rate-protocol was repeated (60-180-60 per minute). Thereafter, ranolazine was washed out followed by another rate change to reconfirm baseline characteristics. Following the same principle, the Na + K + 2Cl− cotransporter-inhibitor furosemide (50 µM) and NHE-inhibitor amiloride (50 µM) were studied sequentially. Ranolazine was provided by Gilead Sciences (Foster City, CA). Furosemide and amiloride were purchased from Sigma-Aldrich (St. Louis, MO).
Statistical Approach
Data are presented as means, SDs, and as standard errors for graphs. Clinical characteristics of patients in CTR, HHD, and HHD+HFpEF groups were compared using 1-way fixed effects ANOVA models for continuous items and by 2×3 contingency table likelihood ratio χ 2 methods for binary items. Only when significant overall results were observed (P<0.05) were a priori specified individual-paired comparisons examined using Fisher least significant difference for ANOVA results or Fisher exact test for contingency tables to maintain a 5% comparison-wise type I error rate. Key findings were confirmed using the Tukey test as reported in the Data Supplement. Baseline and treatment relaxation parameters for inhibition studies were converted to change scores and percentage change scores before examination by ANOVA approaches. Linear and multiple linear regression models were implemented for characterizing RT with LV filling pressures (LVEDP) and other clinical measures, for example, age. Statistical sensitivity analyses were performed using nonparametric Kruskal-Wallis rank tests as 1-way ANOVA analogs to complement parametric ANOVA results to explore potential issues with ANOVA assumptions. Within-preparation comparisons at 60 and 180 per minute were analyzed by paired t test. Formal tests used a 5% significance level. Data analysis was conducted using SYSTAT, version 11 (Richmond, CA).
RESULTS
Patient Characteristics and Diagnostic Parameters
Patients with HHD and HHD+HFpEF tended to be older than CTR patients. There was a higher percentage of women in the HHD+HFpEF group compared with CTR and HHD (Table 1) . Ejection fraction was similar in each group. Compared with CTR, a progressive increase in absolute and relative LV wall thickness, LV mass, left atrial volume, pulmonary artery pressures and worsening diastolic function parameters were observed in HHD and HHD+HFpEF (Table 1 ). This was paralleled by higher LVEDP and NT-proBNP levels.
Myocardial Relaxation in HHD and HHD+HFpEF
Analysis of myocardial contraction at 60 per minute demonstrated a prolongation of relaxation in myocardium of HHD patients, which was most pronounced in patients with HFpEF, as shown in Figure 1 and Figure  I in the Data Supplement. When compared with CTR patients, half maximal RT (RT 50 ) was prolonged by 13% in HHD (P<0.05) and 18% in HHD+HFpEF (P<0.001). Time to 90% relaxation (RT 90 ) was prolonged by 28% (P<0.001), and the RT constant τ was prolonged by 49% (P<0.001) in HHD+HFpEF. As shown in Figure 1 , relaxation was faster at rates of 180 per minute but remained prolonged in myocardium of patients with HHD with and without HFpEF compared with CTRs. In a combined analysis of all patients, irrespective of group status, there was a positive correlation between RT50 and LVEDP (P<0.01; r 2 =0.17) as shown in Figure II in the Data Supplement. This relationship was not present within the groups to support that RT50 was associated with the group status on the biological continuum of LVEDPs. Importantly, RT50 was not associated with age. As shown in Figure IA in the Data Supplement, the key findings were confirmed if a conservative post hoc analysis was applied.
Myocardial Contraction Time in HHD and HHD+HFpEF
In addition to slowing of relaxation, contraction time, measured as time to peak tension, was prolonged in myocardium from patients with HHD and HHD+HFpEF compared with CTRs. At a rate of 60 per minute, time to peak tension was prolonged by 12% in HHD and by 11% in HHD+HFpEF (both P<0.05); at a rate of 180 per minute, time to peak tension was prolonged by 8% and 9%, respectively (both P<0.05). Thus, slowing of both contraction and relaxation contribute to a prolongation of the mechanical cycle.
Incomplete Relaxation and Force Parameters
In myocardium from patients with HHD and HHD+HFpEF, relaxation could not be completed at high rates, which resulted in an incremental increase in diastolic tension (P<0.01). As shown in Figure 2 and Figure IB in 
Incomplete Relaxation, Calcium, and Sodium
Incomplete relaxation in HHD and HFpEF was associated with an inadequate recovery of diastolic Ca 2+ levels at increasing rates, as demonstrated in Figure 3 . The inability to restore diastolic Ca 2+ levels was most pronounced at the highest rate of 180 per minute. Changes in diastolic Ca 2+ were best appreciated after a sudden rate increase from 60 to 180 per minute, as shown in Figure 4 . When normalized to the Ca 2+ transient at 60 per minute, end-diastolic levels rose by 25±13% when rate was increased to 180 per minute in CTR preparations (P<0.05) and 28±14% in HHD and HFpEF preparations (P=0.01). In CTR, this increase in Ca 2+ was only associated with a minor increase in diastolic tension. Although there was no visible rate-dependent change in the Na + signal, analysis of the data revealed a 0.5% increase at 180 per minute in a pooled analysis of HHD and HHD+HFpEF (P<0.05). There was no such change in CTR preparations.
Calcium and Sodium Handling Proteins and Elemental Analysis
When compared with CTR, total myocardial Ca-levels were not significantly different in HHD myocardium but were elevated by 86% in HHD+HFpEF (P<0.01), as shown in Table 2 and Figure III in the Data Supplement. Total myocardial Na was not different between the A indicates A-wave peak velocity; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BSA, body surface area; CAD, coronary artery disease; CCB, calcium channel blocker; CTR, control patient; DBP, diastolic blood pressure; DM, diabetes mellitus; E, E-wave peak velocity; E/E′lat, ratio of mitral peak velocity of early filling (E) to early diastolic lateral mitral annular velocity; E/E′med, ratio of mitral peak velocity of early filling (E) to early diastolic septal mitral annular velocity; EF, ejection fraction; H, height; HFpEF, heart failure with preserved ejection fraction; HHD, hypertensive heart disease; HR, heart rate; LA, left atrial; LV, left ventricle; LVEDD, left ventricular end-diastolic diameter; LVEDP, left ventricular end-diastolic pressure; LVESD, left ventricular end-systolic diameter; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAP, pulmonary artery systolic pressure; RWT, relative wall thickness; and SBP, systolic blood pressure.
CTR groups. The only other difference in elemental analysis was an increase in myocardial copper levels by 30% in HHD+HFpEF compared with CTR (P<0.05). Quantitative polymerase chain reaction did not demonstrate significant differences in the expression levels of any calcium cycling proteins or sodium transporters ( Figure 5) . A trend toward lower phospholamban mRNA levels was seen in HHD and HHD+HFpEF, but this 
Sodium Influx Inhibition
Ranolazine, furosemide, and amiloride did not improve any of the relaxation parameters in CTR, HHD, or HHD+HFpEF, nor did they prevent incomplete relaxation at high rates, as shown in Figure 6 . 
DISCUSSION
As reported in clinical and pathological studies, HHD with concentric LV remodeling is the most common myocardial substrate for HFpEF. [29] [30] [31] [32] Among HFpEF patients enrolled in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), the majority demonstrated echocardiographic evidence of concentric remodeling and a high prevalence of indirect markers of diastolic dysfunction, such as increased left atrial volume and elevated pulmonary arterial pressure. 30 This study also revealed the limitations of clinical methods used to assess relaxation times because they are sensitive to factors, such as loading conditions, heart rate, and neurohormonal activation. A landmark study by Zile et al 33 reported an increase of the time constant of isovolumetric pressure decline (τ) in HFpEF. However, slowed relaxation as an intrinsic property of the myocardium in HFpEF has never been directly demonstrated. We, therefore, set out to quantify the relaxation characteristics of isolated myocardium from patients with HFpEF and its major antecedent disease substrate, HHD. As previously, we obtained viable myocardial biopsies from patients undergoing surgical coronary revascularization. 7, 12 Although this introduces coronary artery disease as a potential confounding factor, angiographic severity was similar in controls, HHD, and HHD+HFpEF. Moreover, coronary artery disease is common in patients with HFpEF; thus, this is a real life cohort. 34 
Contraction and Relaxation at Low Rates
The clinical and echocardiographic characteristics of our HHD+HFpEF cohort were similar to those of patients enrolled in contemporary clinical and biopsy studies. 7, 32 As expected, patients with HHD+HFpEF had elevated LVEDPs and increased NT-proBNP levels in comparison with controls and HHD patients. The HFpEF cohort also had more female patients. At the myocardial level, we found that several measures of relaxation (RT 50 , RT 90 , and τ) were significantly prolonged.
We also found a smaller but significant prolongation of the systolic portion of the contraction, which when added to the slowing in relaxation, further shortens the diastolic interval and, thus, increases the risk for incomplete relaxation even at low heart rates. These data demonstrate for the first time that prolongation of cardiac contraction and relaxation is an intrinsic property of HFpEF myocardium that is independent of the external factors listed above, as well as the lusitropic effects of circulating neurohumoral and inflammatory factors. [35] [36] [37] Our enrollment criteria also yielded a cohort of patients with concentric remodeling caused by hypertension without heart failure (HHD), thus, providing insights into the contraction characteristics of myocardium from patients with a myocardial substrate antecedent to HFpEF. The HHD cohort revealed a level of concentric LV remodeling and diastolic dysfunction that is between CTR and HFpEF patients. Diastolic and systolic time parameters were also prolonged in this group but less so compared with HFpEF. Thus, changes in contraction and relaxation constitute a continuum as the myocardium progresses from normal to HFpEF in response to hypertension.
Contraction and Relaxation at High Rates
When the stimulation rate was increased from 60 to 180 per min, we found that contractile force development was maintained in myocardium from HHD and CTR patients, despite an increase in diastolic tension in HHD. This may suggest a preserved force-frequency relationship, similar to historical findings in comparable groups of patients with additional medical conditions, such as diabetes mellitus. 38 The rate-induced increase in diastolic tension in HHD and HHD+HFpEF is a direct result of a prolonged contraction and relaxation that cannot be overcome by twitch acceleration, thus, resulting in incomplete myocardial deactivation. A trend toward lower developed contractile force in HHD+HFpEF and the inability to maintain contractile force at high rates may also suggest a limitation in systolic function and contractile reserve. This may have a parallel in the clinically documented reduction in LV strain in HFpEF patients. 30 Because an increase in heart rate is by far the most important determinant of cardiac output and force tracing recorded during ≈500 s with a stepwise increase of stimulation rate from 60 to 180/min. This demonstrates a rate-dependent incremental increase in diastolic force that is paralleled by a simultaneous rise in diastolic Ca 2+ levels.
reserve in healthy individuals, it is surprising how little consideration has been given to the effects of heart rate changes in HFpEF. 39 Tachycardia-induced impingement on LV relaxation would be manifest as a reduction in end-diastolic LV volume, thus, limiting or negating the usual potentiating effects of heart rate on stroke volume and cardiac output. Because cardiac output reserve is closely linked to exercise capacity, this mechanism may contribute to the reduced exercise tolerance in patients with HHD and HFpEF. We recently confirmed the presence of this tachycardia-induced LV volume loss in patients with a poor exercise capacity and concentric LVH. 40 This mechanism is also clinically exploited during the balloon expansion of percutaneously delivered valves in patients with aortic stenosis, who share many HFpEF characteristics. In these patients, pacing rates of ≈180 per minute reliably reduce LV stroke volumes and cardiac output to allow for the deployment of the valve.
Role of Calcium and Copper
In myocardium from patients with diastolic dysfunction and concentric LVH, we recently described a sarcolemmal Ca 2+ -extrusion deficit. 12 These studies suggested that intracellular Ca 2+ levels were markedly elevated at high stimulation rates. At 180 per minute, the deficit in cellular Ca 2+ extrusion could not be compensated by an increase in sarcoplasmic reticulum Ca 2+ uptake, which may explain why we found a reduction in contractile force in HHD+HFpEF in the present study. Our experiments with Fura-2 are not quantitative but demonstrate the presence of a rate-dependent rise in diastolic-free Ca
2+
. However, in controls, this did not translate into a meaningful rise in diastolic tension. This may indicate that myocardial Ca 2+ levels are generally lower in control myocardium. Indeed, this was confirmed in the elemental analysis. The total resting myocardial Ca 2+ content was nearly twice as high in HHD+HFpEF myocardium when compared with CTR. This would also explain why we found resting myofilament activation in , and force tracings in myocardium from a control patient (CTR) and a patient with hypertensive heart disease (HHD) with a rate change from 60 to 180/min. A small increase in diastolic Ca 2+ in the CTR sample after the rate change to 180/min is not paralleled by an increase in diastolic tension; in the HHD sample, a more pronounced increase of diastolic force and Ca 2+ is noted. There is no obvious change in the corecorded Na + signal (ANG-2) in both CTR and HHD.
our previous study, which was not because of changes in myofilamental calcium sensitivity.
When the current and previous findings 12 are viewed together, our results demonstrate increased myocardial Ca 2+ levels as shown by the elemental analysis, a rate-induced increase in diastolic cytosolic Ca 2+ levels as shown by Fura-2, and a marked overloading of the sarcoplasmic reticulum at 180 per minute as demonstrated by rapid-cooling contractures and postrest contractions. This confirms that a disturbance in Ca 2+ handling plays a significant role in myocardium of patients with diastolic dysfunction and HFpEF. Unexpectedly, we also found copper levels to be elevated in HHD+HFpEF. Copper is an essential cofactor for a small number of enzymes, most notably lysyl oxidases (LOX and LOXL), which crosslink collagen fibrils in the extracellular matrix. Higher copper levels might result in a higher lysyl oxidase activity, which could thereby contribute to increased collagen-dependent stiffness in HFpEF. 41, 42 
Na
+ Paradigm in HFpEF
Because cellular Ca 2+ extrusion depends on the transsarcolemmal Na + gradient, we simultaneously recorded intracellular Na + in our preparations. We did not find a substantial change in the Na + signal with an increase in rate. This finding was confirmed with the alternative Na + -indicator sodium-binding benzofuran isophthalate (data not shown). In addition, resting myocardial Na levels by elemental analysis were not different in HFpEF. These results suggest a major difference between HFpEF and end-stage heart failure with reduced ejection fraction (HFrEF), where intracellular Na + levels are reported to increase by ≈20% when the stimulation rate is increased from 60 to 180 per minute. 43 The lack of a change in Na + makes this an unlikely explanation for the deficit in cellular Ca 2+ extrusion observed in HFpEF. More quantitative and spatially restricted assessments of intracellular ion levels can now be obtained in single cardiac myocytes. These would be of great interest in understanding the ion changes we observed in HFpEF. Unfortunately, this approach is not feasible in our epicardial biopsies because they lack appropriate vascular access to deliver digestive enzymes to isolate myocytes. As mentioned above, an enhancement of the sarcolemmal Na + gradient has been put forward as a treatment for HFpEF because it might promote cellular Ca 2+ extrusion via the sarcolemmal NCX. Conceptually, this could accelerate relaxation and thereby prevent incomplete relaxation. An improvement of the Na + gradient may be achieved by reducing Na + influx through highcapacity importers. 13 The cardiac Na + -channel late current is a potential target after a recent proof-of-concept Left, Original tracing of a myocardial preparation obtained from a patient with hypertensive heart disease (HHD), which was sequentially exposed to 10 µM ranolazine, 50 µM furosemide, and 50 µM amiloride. Incomplete relaxation at 180/min was not affected by any of the Na + -influx inhibitors. Right, Relaxation time parameters (relaxation time [RT 50 ], RT 90 , and τ) obtained at 60/min in myocardium from control patients (n=8), HHD (n=7), and HHD+heart failure with preserved ejection fraction (HFpEF; n=4). After a baseline measurement without inhibitor relaxation was sequentially assessed with ranolazine, furosemide, and amiloride. No changes in relaxation time parameters were noted. CTR indicates control patient. study in HFpEF patients suggested some hemodynamic benefits of ranolazine. 21 This current was initially discovered in cardiac myocytes from patients with HFrEF. 16 Favorable effects of ranolazine on relaxation were reported in a rat model of HFrEF and in isolated myocardium from patients with end-stage HFrEF. 15, 19, 20 Another high-capacity Na + -import mechanism is the furosemide-sensitive Na + K + 2Cl − cotransporter. Na + K + 2Cl − cotransporter activity has been documented in ventricular myocytes. Inhibition of this transporter in cardiac myocytes could also provide a novel explanation for the diuresis-independent early hemodynamic effects of furosemide. 13, [44] [45] [46] The amiloride-sensitive NHE-1 is another significant source of Na + influx into cardiac myocytes. 13, 47 Angiotensin II, endothelin, and slow stretch activation are known activators of NHE-1.
47,48 Na + influx through NHE-1 has been suggested to promote concentric LVH through Ca 2+ -dependent mechanisms. 49, 50 In a small patient study, amiloride was reported to improve exercise hemodynamics and LVEDP in heart failure patients. 51 Our results suggest that none of these agents can improve myocardial relaxation in HFpEF or prevent incomplete relaxation at high rates. They also suggest that increased Na + is an unlikely culprit underlying slowed and incomplete relaxation in HHD and HHD+HFpEF, likely because the cellular Na + / K + -ATPase is capable of maintaining normal Na + levels.
Ion Transporters and Regulatory Proteins
Expression levels of Ca
2+
-and Na + -handling and regulatory proteins were also not different in HHD or HHD+HFpEF compared with control. This is another major difference compared with the findings in HFrEF and its signature reduction of the sarcoplasmatic Ca 2+ -ATPase and increase in NCX. 27, 52 Our expression analysis also suggests that unchanged levels of α and β MHC do not provide an alternative explanation for a slowed relaxation. This is consistent with our prior findings that Ca 2+ sensitivity of the sarcomeric proteins is unchanged. 12 It is possible that no single mechanism will be found to explain the dysregulation of Ca 2+ handling in HFpEF. Thus, a combination of factors, such as spatial subcellular alterations, for example, rarefication of T-tubules or post-translational protein modifications, may contribute to insufficient clearance of Ca 2+ from the cytosol. This may involve hypophosphorylated protein kinase A/protein kinase G sites, which have been shown to contribute to increased stiffness of sarcomeric proteins, that is, troponin I, myosin-binding protein C, and structural proteins, such as titin. 9, 11, [53] [54] [55] 
Limitations
The comparably low normalized forces in this study confirm a high variability of this calculated parameter. This is most likely because of the procurement, sculpting technique, fiber orientation, weight assessment, and the equipment used but not because of an impaired energy supply as evident in normal human contraction and relaxation kinetics.
Conclusions
In summary, our data demonstrate the presence of prolonged myocardial relaxation with an additional prolongation of the systolic phase of the mechanical cycle in patients with HHD and HFpEF. These are intrinsic properties of the myocardium in these patients, which result in incomplete relaxation at high heart rates. Elevated myocardial calcium levels are present, but this does not seem to be sodium-dependent, which explains why Na + -influx inhibition with ranolazine, furosemide, or amiloride did not improve myocardial relaxation. The mechanism(s) that underlie the myocardial calcium overload in HFpEF remain to be elucidated but are likely multifactorial.
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